SCHEMBL6098722

SCHEMBL6098722

Cc1nc(S(N)(=O)=O)sc1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 15/20 0.45
CA1 P00915 12/20 0.45
CA4 P22748 11/20 0.45
CA9 Q16790 9/20 0.45
CA12 O43570 7/20 0.45
CA14 Q9ULX7 7/20 0.45
CA5A P35218 7/20 0.45
CA7 P43166 6/20 0.45
CA6 P23280 6/20 0.45
CA5B Q9Y2D0 6/20 0.45
CA13 Q8N1Q1 4/20 0.45
NOS1 P29475 1/20 0.44
CA3 P07451 3/20 0.39
MEN1 O00255 1/20 0.39
CA11 O75493 1/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23569833 0.83 NOS1 (0.41) CA2CA1CA4CA9CA12
SCHEMBL113995 0.79 NOS1 (0.41) CA2CA1CA4CA5ACA5B
SCHEMBL7476144 0.77 NOS1 (0.39) NOS1MEN1KMT2ASMN1; SMN2
SCHEMBL23569112 0.77 NOS1 (0.39) NOS1SMN1; SMN2
SCHEMBL21893023 0.72 CA2 (0.37) CA2CA1CA4CA9CA12
SCHEMBL19505677 0.72 CA2 (0.37) CA2CA1CA4CA9CA12
SCHEMBL9094599 0.70 CHRNA7 (0.52) CA2CA1CA4CA9CA12
SCHEMBL10711085 0.70 CA2 (0.58) CA2CA1CA4CA9CA12
SCHEMBL9796194 0.69 CA2 (0.71) CA2CA1CA4CA9CA12
SCHEMBL21893022 0.68 GAA (0.50) CA2CA1CA4CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use Oxford Drug Design Limited (GB) 2025-03-11 US disclosed
CN-114846000-B 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof 牛津药物设计有限公司 2025-01-03 CN disclosed
US-20230114875-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2023-04-13 US disclosed
EP-4077289-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2022-10-26 EP disclosed
CN-114846000-A 2-amino-N- (amino-oxo-aryl- λ 6-thioalkyl) acetamide compounds and therapeutic uses thereof 牛津药物设计有限公司 2022-08-02 CN disclosed
WO-2021123237-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2021-06-24 WO disclosed
WO-2021123237-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2021-06-24 WO disclosed
CN-101472902-A Novel piperazine compounds and their use as HCV polymerase inhibitors JAPAN TOBACCO INC (JP) 2009-07-01 CN disclosed
US-7001917-B2 Pyrazole compounds as anti-inflammatory and analgesic agents WARNER LAMBERT COMPANY LLC (US) 2006-02-21 US disclosed
EP-1495005-A1 PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS Pfizer Japan Inc. (JP) 2005-01-12 EP disclosed
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents HIRANO MISATO (JP) 2004-01-29 US disclosed
WO-2003087061-A1 PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER JAPAN INC. (JP) 2003-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use AARS1, ASNS, GARS1 CA2 2761/4885CA1 4200/4885CA4 4524/4885
US-20040019045-A1 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents PTGER1, PTGS1, PTGIR CA2 230/4885CA1 1837/4885CA4 1429/4885
US-20230114875-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AARS1, ASNS, GARS1 CA2 2761/4885CA1 4200/4885CA4 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.